IMCD N.V. (AMS:IMCD)
Netherlands
· Delayed Price · Currency is EUR | Market Cap | 5.76B |
| Revenue (ttm) | 4.81B |
| Net Income (ttm) | 217.58M |
| Shares Out | 59.03M |
| EPS (ttm) | 3.68 |
| PE Ratio | 26.53 |
| Forward PE | 16.99 |
| Dividend | 1.81 (1.85%) |
| Ex-Dividend Date | May 5, 2026 |
| Volume | 201,842 |
| Average Volume | 273,252 |
| Open | 98.08 |
| Previous Close | 98.08 |
| Day's Range | 97.40 - 99.42 |
| 52-Week Range | 68.14 - 126.55 |
| Beta | 0.95 |
| RSI | 72.01 |
| Earnings Date | Apr 30, 2026 |
About IMCD N.V.
IMCD N.V. distributes, markets, and sells specialty chemicals and ingredients in the Netherlands, rest of Europe, the Middle East, Africa, North America, South America, and the Asia-Pacific. The company provides adhesives, core materials, filler reinforcements, flame retardants, masterbatch, modifiers, operating materials, pigments, plasticizers, processing aids, PUR raw materials, rubber elastomers, solvents, stabilizers, thermoplastic elastomers, thermoplastics, thermoplastics, and other additives. It offers actives, UV sunscreens, rheology m... [Read more]
Financial Performance
In 2025, IMCD N.V.'s revenue was 4.81 billion, an increase of 1.23% compared to the previous year's 4.75 billion. Earnings were 217.58 million, a decrease of -21.80%.
Financial StatementsNews
IMCD Shares Plunge After Dividend Cut, Revenue Fall
Shares in the chemicals and food ingredients distributor were down 14%, and the company said waning demand across its markets and regions stalled organic growth in 2025.
IMCD N.V. Earnings Call Transcript: Q4 2025
2025 saw strong early growth but was followed by challenging quarters due to macroeconomic and currency headwinds, leading to softer demand and lower margins. Acquisitions and strategic initiatives supported stability, while management remains cautiously optimistic for 2026.
IMCD N.V. Earnings Call Transcript: Q3 2025
Gross profit and revenue grew year-over-year despite macroeconomic and tariff headwinds, with acquisitions contributing to top-line growth. Margin pressure stemmed from mix and M&A, while digital initiatives and cost controls are being intensified. Leverage remains stable, and management is confident in long-term prospects.
IMCD N.V. Earnings Call Transcript: Q2 2025
Gross profit and EBITDA grew in H1 2025, but Q2 saw demand soften amid global uncertainty and currency headwinds. Working capital and net debt increased due to higher inventories and acquisitions, while pharmaceutical and food & nutrition segments remained resilient.
IMCD N.V. Earnings Call Transcript: Q1 2025
Q1 2025 delivered double-digit profit and EBITA growth despite global uncertainty and tariffs. Americas and Asia Pacific drove strong results, while EMEA lagged due to inflation. CEO transition completed, with a robust M&A pipeline and no strategic disruptions.
IMCD N.V. Earnings Call Transcript: Q4 2024
Gross profit and EBITDA grew after a weak Q1, with strong M&A activity and a healthy order book. Margins were pressured by inflation, but leverage and cash flow remain strong. Outlook is positive but cautious due to ongoing geopolitical and market volatility.
IMCD N.V. Earnings Call Transcript: Q3 2024
Revenue and EBITDA grew in the first nine months, driven by acquisitions and organic gains, with all regions showing Q3 improvement. Market volatility and limited visibility persist, but digital and sustainability investments continue, and leverage remains well below covenants.
IMCD N.V. Earnings Call Transcript: Q2 2024
Revenue for H1 2024 was EUR 2.385 billion with operating EBITDA of EUR 270 million, reflecting a 2% decrease year-over-year due to a weak Q1 but strong Q2 recovery. Eleven acquisitions supported growth, while market volatility and limited visibility persist.
IMCD N.V. Earnings Call Transcript: Q1 2024
IMCD N.V. Earnings Call Transcript: Q4 2023
IMCD Colombia to acquire the distribution business of Joli Foods S.A.S. to strengthen its food and nutrition portfolio
ROTTERDAM, The Netherlands (27 December 2023) – IMCD N.V. (“IMCD” or “Company”), a global leading distribution partner, and formulator of speciality chemicals and ingredients, today announces that IMC...
IMCD N.V. Earnings Call Transcript: Q3 2023
IMCD N.V. Earnings Call Transcript: Q2 2023
IMCD Israel expands its Beauty & Personal Care presence with the acquisition of Tagra Biotechnologies Distribution Division
ROTTERDAM, The Netherlands (1st May 2023) – IMCD N.V. (“IMCD” or “Company”), a leading distributor of speciality chemicals and ingredients, today announces that IMCD Israel has acquired the import and...